Focus-X Therapeutics

Focus-X Therapeutics is a preclinical-stage biotechnology company focused on developing next-generation radiopharmaceuticals for cancer diagnosis and therapy, particularly solid tumors with low five-year survival rates. Their approach leverages proprietary peptide radioligands to precisely deliver alpha or beta emitters to cancer cells, aiming to improve on existing therapies by optimizing biodistribution and reducing off-target effects. The company has advanced multiple candidates to the investigational new drug (IND)-enabling stage, with a particular emphasis on PSMA-targeted therapies for prostate cancer and novel agents for pancreatic cancer. Their lead PSMA-Ac225 program is differentiated by potentially lower salivary gland uptake compared to competitors, which could reduce dose-limiting toxicity. The company was acquired by Full-Life Technologies to strengthen both parties' positions in the radiopharmaceutical field[2].